Get the Stockscreener App
4.58
0.87%
-0.04
Apimeds Pharmaceuticals US, Inc. Stock (APUS) Forecast
The Apimeds Pharmaceuticals US, Inc. (APUS) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $6.4043, representing a +39.83% increase from the current price of $4.58. The highest analyst price target is $10.04, and the lowest is $2.7671.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month APUS Price Target
Average 25.50
(+456.67% Upside)
Is Apimeds Pharmaceuticals US, Inc. (APUS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 50.46 | Neutral |
| STOCH(9,6) | 33.09 | Neutral |
| STOCHRSI(14) | 12.91 | Buy |
| MACD(12,26) | 0.4102 | Buy |
| ADX(14) | 32.17 | Buy |
| William %R | -78.04 | Neutral |
| CCI(14) | -38.14 | Neutral |
Buy: 3
Sell: 0
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
5.102
Sell
|
4.9845
Sell
|
| MA20 |
4.4425
Buy
|
4.6296
Sell
|
| MA50 |
3.9711
Buy
|
4.8277
Sell
|
| MA100 |
6.7683
Sell
|
6.9409
Sell
|
| MA200 |
11.91
Sell
|
11.61
Sell
|
Buy: 2
Sell: 8
Neutral: 0
Summary: Sell
According to our latest analysis, APUS could be considered a Moderate Sell, with 17 technical analysis indicators signaling 5 Buy signals, 8 signaling Sell signals and 4 Neutral signals. This might not be a good time to consider opening new positions on APUS, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 50.46 indicates that APUS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 33.09 indicates that APUS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 12.91 indicates that APUS is oversold. This suggests that APUS price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 32.17 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -38.14 indicates that APUS is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term APUS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Apimeds Pharmaceuticals US, Inc. financial reports and earnings history, Apimeds Pharmaceuticals US, Inc. (APUS) stock could reach $11.57 by 2030, $55.71 by 2040 and $99.34 by 2050. See the projected annual prices until 2050 of the Apimeds Pharmaceuticals US, Inc. stock below:
- Apimeds Pharmaceuticals US, Inc. (APUS) is expected to reach an average price of $61.30 in 2035, with a high prediction of $67.19 and a low estimate of $64.65. This indicates an $1,238% rise from the last recorded price of $4.58.
- Apimeds Pharmaceuticals US, Inc. (APUS) stock is projected to chart a bullish course in 2040, with an average price target of $45.67, representing an $897.08% surge from its current level. The forecast ranges from a conservative $45.79 to a sky-high $55.71.
- Our analysts predict Apimeds Pharmaceuticals US, Inc. (APUS) to jump 3,142% by 2045, soaring from $151.83 to an average price of $148.48, potentially reaching $161.35. While $151.83 is the low estimate, the potential upside is significant.
- Apimeds Pharmaceuticals US, Inc. (APUS) stock is expected to climb by 2050, reaching an average of $82.33, a $1,698% jump from its current level. However, a wide range of estimates exists, with high and low targets of $99.34 and $82.45, respectively, highlighting the market's uncertainty.
Apimeds Pharmaceuticals US, Inc. Stock (APUS) Year by Year Forecast
Apimeds Pharmaceuticals US, Inc. Stock (APUS) Price Forecast for 2026
The predicted value for Apimeds Pharmaceuticals US, Inc. (APUS) in 2026 is set at an average of $30.61. Estimates vary from a peak of $59.70 to a trough of $1.51, indicating an +568.23% surge from the present price of $4.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| November, 2026 | $8.3414 | $2.7671 | $10.04 | +82.13% |
| December, 2026 | $16.22 | $5.0157 | $27.33 | +254.05% |
Apimeds Pharmaceuticals US, Inc. Stock (APUS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Apimeds Pharmaceuticals US, Inc. (APUS) is $25.50, with a high forecast of $50.98 and a low forecast of $0.0102. This indicates an +456.67% increase from the last price of $4.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $5.7899 | $2.7964 | $20.61 | +26.42% |
| February, 2027 | $5.8642 | $3.7835 | $11.86 | +28.04% |
| March, 2027 | $3.629 | $0.9515 | $18.96 | -20.76% |
| April, 2027 | $11.11 | $1.7256 | $11.51 | +142.50% |
| May, 2027 | $6.5741 | $3.8741 | $50.98 | +43.54% |
| June, 2027 | $5.0484 | $3.2484 | $7.8613 | +10.23% |
| July, 2027 | $2.0227 | $0.5385 | $8.1355 | -55.84% |
| August, 2027 | $1.7795 | $0.0102 | $3.0358 | -61.15% |
| September, 2027 | $1.3552 | $1.5052 | $1.1452 | -70.41% |
| October, 2027 | $2.789 | $2.6417 | $4.679 | -39.10% |
| November, 2027 | $10.14 | $0.3297 | $10.14 | +121.40% |
| December, 2027 | $9.4915 | $10.09 | $9.7617 | +107.24% |
Apimeds Pharmaceuticals US, Inc. Stock (APUS) Price Forecast for 2028
In 2028, Apimeds Pharmaceuticals US, Inc. (APUS) is projected to reach an average price of $21.69, with a high projection of $42.26 and a low estimate of $1.1131. This indicates an +373.52% rise from the last price of $4.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $3.1558 | $3.4429 | $14.35 | -31.10% |
| February, 2028 | $9.2073 | $4.1444 | $8.0185 | +101.03% |
| March, 2028 | $6.2587 | $6.4587 | $6.3459 | +36.65% |
| April, 2028 | $5.1102 | $5.6845 | $7.9155 | +11.58% |
| May, 2028 | $3.1745 | $6.5245 | $6.3488 | -30.69% |
| June, 2028 | $0.974 | $1.1131 | $2.0126 | -78.73% |
| July, 2028 | $3.1903 | $3.3775 | $42.26 | -30.34% |
| August, 2028 | $5.3418 | $4.3661 | $3.4198 | +16.63% |
| September, 2028 | $7.1433 | $5.4457 | $4.3933 | +55.97% |
| October, 2028 | $6.9876 | $7.121 | $6.642 | +52.57% |
| November, 2028 | $7.5391 | $6.7405 | $7.2262 | +64.61% |
| December, 2028 | $2.7405 | $3.5505 | $3.0577 | -40.16% |
Apimeds Pharmaceuticals US, Inc. Stock (APUS) Price Forecast for 2029
The 2029 price forecast for Apimeds Pharmaceuticals US, Inc. Stock (APUS) is $18.33 on average, with a high prediction of $33.54 and a low estimate of $3.1234. This represents an +300.27% increase from the previous price of $4.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $23.62 | $3.1234 | $24.86 | +415.67% |
| February, 2029 | $17.80 | $19.90 | $22.34 | +288.54% |
| March, 2029 | $16.37 | $16.61 | $8.353 | +257.47% |
| April, 2029 | $18.22 | $16.54 | $17.97 | +297.79% |
| May, 2029 | $14.05 | $16.73 | $14.39 | +206.68% |
| June, 2029 | $16.62 | $17.77 | $16.42 | +262.95% |
| July, 2029 | $9.4257 | $10.22 | $15.14 | +105.80% |
| August, 2029 | $9.9969 | $10.04 | $33.54 | +118.27% |
| September, 2029 | $11.77 | $11.34 | $8.5741 | +157.08% |
| October, 2029 | $13.17 | $12.42 | $11.23 | +187.57% |
| November, 2029 | $12.90 | $13.22 | $12.60 | +181.61% |
| December, 2029 | $12.44 | $11.98 | $12.07 | +171.60% |
Apimeds Pharmaceuticals US, Inc. Stock (APUS) Price Forecast for 2030
Apimeds Pharmaceuticals US, Inc. Stock (APUS) is expected to reach an average price of $23.20 in 2030, with a high forecast of $39.58 and a low forecast of $6.8101. This signifies an +406.44% surge from the last price of $4.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $9.0015 | $8.1722 | $11.57 | +96.54% |
| February, 2030 | $40.31 | $6.8101 | $39.58 | +780.04% |
| March, 2030 | $35.21 | $37.81 | $38.43 | +668.75% |
| April, 2030 | $22.14 | $29.79 | $30.63 | +383.35% |
| May, 2030 | $30.24 | $28.94 | $27.11 | +560.27% |
| June, 2030 | $27.84 | $28.74 | $29.59 | +507.93% |
| July, 2030 | $27.17 | $27.77 | $25.35 | +493.34% |
| August, 2030 | $17.37 | $23.70 | $26.50 | +279.36% |
| September, 2030 | $19.00 | $18.95 | $24.82 | +314.92% |
| October, 2030 | $18.21 | $19.28 | $17.83 | +297.52% |
| November, 2030 | $18.91 | $19.40 | $18.21 | +312.87% |
| December, 2030 | $19.81 | $19.81 | $18.61 | +332.49% |
1.53%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):